Incidentally, 5-aminosalicylic acid (5-ASA), which is widely used in the treatment of IBD, is also a PPARγ ligand (Rousseaux et al., 2005; Iacucci et al., 2010). Here, PPARG is linked to inflammatory bowel disease.